![](/img/cover-not-exists.png)
A Phase II double blind placebo-controlled multicenter study of the anti-PDGF-β-R Dl-Fab'-PEG conjugate CDP860 (25 mg/kg) dosed intravenously in patients undergoing elective coronary stent placement
Patrick W. Serruys III, Guy Heyndrickx, Hans Bonnier, Matty Vrolix, Frank Van den Branden, Victor Legrand, Claude Hanet, Hans Te Riele, Michael Vandormael, Ivan De ScheerderVolume:
39
Year:
2002
Language:
english
DOI:
10.1016/s0735-1097(02)80301-1
File:
PDF, 166 KB
english, 2002